Welcome to our dedicated page for Cellectis S.A. American Depositary Shares news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis S.A. American Depositary Shares stock.
Cellectis S.A. (symbol: CLLS) is a clinical-stage biopharmaceutical company that specializes in developing cutting-edge cancer immunotherapies using gene-edited T-cells, known as UCART. With over 18 years of experience in gene editing, Cellectis leverages its proprietary TALEN® technology and PulseAgile electroporation system to harness the power of the immune system to combat cancer.
Cellectis is dedicated to creating innovative products in the fields of immuno-oncology and beyond. Its portfolio includes allogeneic Chimeric Antigen Receptor T-cells (CAR-T) product candidates and gene-edited hematopoietic stem and progenitor cells (HSPC) for various therapeutic applications.
Recent achievements include advancements in gene correction and gene insertion technologies, presented at esteemed scientific conferences. For instance, the company has introduced a novel method for circularizing non-viral single-strand DNA templates, enhancing gene editing outcomes in HSPCs. Cellectis is also collaborating with renowned pharmaceutical companies like AstraZeneca, further expanding its pipeline of allogeneic CAR T-cell therapies.
Financially, Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets. The company's ongoing projects and research efforts are supported by robust investment and partnership agreements, showcasing its commitment to improving health outcomes through innovative biotechnological solutions.
For more information, visit the company's website at www.cellectis.com.
Cellectis, a clinical-stage biotechnology company, announced the presentation of preclinical data on TALEN®-edited smart CAR T-cells at the SITC 37th Annual Meeting. The data, focusing on targeting solid tumors, includes two key presentations about MUC-1 CAR T-cells and T-cell engineering strategies that improve anti-tumor efficacy while minimizing toxicity. The innovative approaches address challenges faced by CAR T-cell therapies in solid tumors, particularly triple-negative breast cancer. The presentations are available on Cellectis' website following the event.
Cellectis (ticker: CLLS), a clinical-stage biotechnology company, has published a manuscript in Frontiers Bioengineering and Biotechnology showcasing the effectiveness of a multiplex gene editing approach using TALEN® and TALE base editing technologies. This combination enables efficient double gene knock-outs of TRAC and CD52, essential for allogeneic CAR T-cell therapies, with minimal by-products. The study achieved up to 80% and 75% phenotypic knock-outs respectively, paving the way for safer and more controllable gene editing applications in therapeutic settings.
Cellectis reported as of October 31, 2022, a total of 45,567,810 shares in its capital and 51,634,701 voting rights. This biotechnology company specializes in gene-editing and focuses on developing CAR-T immunotherapies for various cancers. Cellectis employs its proprietary TALEN® technology and PulseAgile system to advance treatments for acute myeloid leukemia and other serious conditions. The company continues to expand its portfolio while maintaining a commitment to address unmet medical needs.
Cellectis reported its Q3 2022 results, highlighting a cash position of $103 million as of September 30, 2022. Revenues fell to $9 million, down from $53 million in the same period last year, primarily due to decreased milestone payments. R&D expenses were $85 million, reflecting notable cost management. The net loss attributable to shareholders decreased to $79 million or $1.74 per share, compared to $89 million in the prior year. Additionally, several clinical trials progressed, including UCART123's upcoming oral presentation at the ASH 2022 Annual Meeting.
Cellectis has announced two abstracts accepted for presentation at the 64th ASH Annual Meeting from December 10-13, 2022. The AMELI-01 study evaluating UCART123 in patients with relapsed/refractory acute myeloid leukemia (r/r AML) will showcase preliminary data, highlighting improved activity with alemtuzumab. Additionally, a poster on UCARTCS1 will present preclinical data demonstrating anti-tumor activity in multiple myeloma. Cellectis aims to address unmet medical needs using its gene-editing platform to develop innovative therapies.
Cellectis, a clinical-stage biotechnology company, is set to announce its Q3 2022 financial results on November 3, 2022, after the US market closes. This will be followed by a conference call on November 4, 2022, at 8:00 AM EDT to discuss the results and provide a business update. Cellectis focuses on developing innovative gene-editing therapies using TALEN® technology and is pioneering off-the-shelf CAR-T immunotherapies. The company is listed on Nasdaq under the symbol CLLS.
Cellectis, a clinical-stage biotechnology company, announced pre-clinical data on TALEN®-edited CAR T-cells aimed at solid tumors, to be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting from November 8-12, 2022. Key presentations include:
- Poster on MUC1-targeting CAR T-cells for triple-negative breast cancer (Poster Number: 217).
- Poster on engineering strategies to enhance CAR T-cell efficacy (Poster Number: 325).
Cellectis utilizes its TALEN® technology to develop innovative therapies for unmet medical needs in oncology.
Cellectis, a clinical-stage biotechnology company focused on gene-editing technology, has appointed Dr. Mark Frattini as Chief Medical Officer, effective immediately. Dr. Frattini has over 20 years of experience in hematological malignancies and was previously Senior Vice President of Clinical Sciences at Cellectis. His role will encompass overseeing clinical research and development for the company's UCART clinical trial programs. Dr. Frattini's extensive expertise aims to advance the company’s CAR T-cell therapies, addressing critical patient needs in blood cancer treatment.
Cellectis, a clinical-stage biotechnology company, is advancing its gene-editing technology, TALEN®, to develop innovative cell therapies for cancer treatment. As of August 31, 2022, the company reported a total of 45,550,810 shares in capital and 51,615,672 voting rights. With over 22 years of expertise in gene editing, Cellectis focuses on off-the-shelf CAR-T therapies aimed at various blood cancers, including AML and B-ALL. The company is listed on both the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
FAQ
What is the current stock price of Cellectis S.A. American Depositary Shares (CLLS)?
What is the market cap of Cellectis S.A. American Depositary Shares (CLLS)?
What does Cellectis S.A. specialize in?
What proprietary technologies does Cellectis use?
What are UCART cells?
What recent advancements has Cellectis made?
Which companies has Cellectis partnered with?
On which stock markets is Cellectis listed?
What are HSPCs?
How long has Cellectis been in the gene editing field?
Where can I find more information about Cellectis?
How does Cellectis contribute to immuno-oncology?
